AP
CORT icon

AHL Partners’s Corcept Therapeutics CORT Stock Holding History

AHL Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.03M Sell
57,097
-65,896
-54% -$1.19M 0.02% 886
2017
Q3 		$2.37M Buy
+122,993
New +$1.83M 0.04% 619

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

AHL Partners's CORT Position: Q4 2017 in Review

AHL Partners reduced its Corcept Therapeutics (CORT) stake by 54% in Q4 2017, selling an estimated $1.19M and leaving 57,097 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #886.

AHL Partners first reported a position in CORT in Q3 2017 and has held it in 2 quarters since. The position peaked at $2.37M in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • AHL Partners held 57,097 shares of Corcept Therapeutics worth $1.03M as of Q4 2017.
  • AHL Partners sold 65,896 Corcept Therapeutics shares in Q4 2017, an estimated $1.19M.
  • Corcept Therapeutics made up 0.02% of AHL Partners's portfolio in Q4 2017, its #886 holding.
  • AHL Partners first reported a position in Corcept Therapeutics in Q3 2017 and has held it in 2 quarters since.
  • AHL Partners's Corcept Therapeutics position peaked at $2.37M in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.